Empowering Early Intervention: Navigating Treatments for Delaying T1D Progression, Insights from AM Diabetes and Endocrinology Center

home / institutional-insights / empowering-early-intervention-navigating-treatments-for-delaying-t1d-progression-insights-from

In this program, a panel of experts in the management of diabetes educate healthcare providers on teplizumab's role in delaying type 1 diabetes stage progression through early intervention. It covers disease staging, screening recommendations, eligibility processes, teplizumab's mechanism of action, and the navigation of the 14-day infusion regimen. By facilitating timely teplizumab access, the program aims to identify at-risk patients, reduce diabetic ketoacidosis, mitigate disease burdens, and improve quality of life.

© 2024 MJH Life Sciences

All rights reserved.